BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 32278699)

  • 1. Does the expression of glial fibrillary acid protein (GFAP) stain in glioblastoma tissue have a prognostic impact on survival?
    Ahmadipour Y; Gembruch O; Pierscianek D; Sure U; Jabbarli R
    Neurochirurgie; 2020 Jun; 66(3):150-154. PubMed ID: 32278699
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy.
    Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD
    Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The correlation and prognostic significance of MGMT promoter methylation and MGMT protein in glioblastomas.
    Cao VT; Jung TY; Jung S; Jin SG; Moon KS; Kim IY; Kang SS; Park CS; Lee KH; Chae HJ
    Neurosurgery; 2009 Nov; 65(5):866-75; discussion 875. PubMed ID: 19834398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is MGMT promoter methylation to be considered in the decision making for recurrent surgery in glioblastoma patients?
    Pala A; Schmitz AL; Knoll A; Schneider M; Hlavac M; König R; Wirtz CR; Coburger J
    Clin Neurol Neurosurg; 2018 Apr; 167():6-10. PubMed ID: 29425743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.
    Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F
    Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Extent of tumor removal and molecular markers in cerebral glioblastoma: a combined prognostic factors study in a surgical series of 105 patients.
    Salvati M; Pichierri A; Piccirilli M; Floriana Brunetto GM; D'Elia A; Artizzu S; Santoro F; Arcella A; Giangaspero F; Frati A; Simione L; Santoro A
    J Neurosurg; 2012 Aug; 117(2):204-11. PubMed ID: 22655594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of MGMT promoter methylation and TP53 mutation in glioblastomas depends on IDH1 mutation.
    Wang K; Wang YY; Ma J; Wang JF; Li SW; Jiang T; Dai JP
    Asian Pac J Cancer Prev; 2014; 15(24):10893-8. PubMed ID: 25605197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy.
    Nguyen HN; Lie A; Li T; Chowdhury R; Liu F; Ozer B; Wei B; Green RM; Ellingson BM; Wang HJ; Elashoff R; Liau LM; Yong WH; Nghiemphu PL; Cloughesy T; Lai A
    Neuro Oncol; 2017 Mar; 19(3):394-404. PubMed ID: 27571882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Charlson comorbidity index: an additional prognostic parameter for preoperative glioblastoma patient stratification.
    Ening G; Osterheld F; Capper D; Schmieder K; Brenke C
    J Cancer Res Clin Oncol; 2015 Jun; 141(6):1131-7. PubMed ID: 25577223
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defining optimal cutoff value of MGMT promoter methylation by ROC analysis for clinical setting in glioblastoma patients.
    Yuan G; Niu L; Zhang Y; Wang X; Ma K; Yin H; Dai J; Zhou W; Pan Y
    J Neurooncol; 2017 May; 133(1):193-201. PubMed ID: 28516344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The combined EGFR protein expression analysis refines the prognostic value of the MGMT promoter methylation status in glioblastoma.
    Tini P; Pastina P; Nardone V; Sebaste L; Toscano M; Miracco C; Cerase A; Pirtoli L
    Clin Neurol Neurosurg; 2016 Oct; 149():15-21. PubMed ID: 27450763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay?
    Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H
    J Neurosurg; 2018 May; 130(3):780-788. PubMed ID: 29726772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of Multifocality and Molecular Markers on Survival of Glioblastoma.
    Ahmadipour Y; Jabbarli R; Gembruch O; Pierscianek D; Darkwah Oppong M; Dammann P; Wrede K; Özkan N; Müller O; Sure U; El Hindy N
    World Neurosurg; 2019 Feb; 122():e461-e466. PubMed ID: 30347300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MGMT promoter methylation status as a prognostic factor for the outcome of gamma knife radiosurgery for recurrent glioblastoma.
    Kim BS; Kong DS; Seol HJ; Nam DH; Lee JI
    J Neurooncol; 2017 Jul; 133(3):615-622. PubMed ID: 28536992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic value of TERT mutation in adults with primary glioblastomas. Preliminary results].
    Zolotova SV; Anoshkin KI; Absalyamova OV; Makashova ES; Belyashova AS; Telysheva EN; Golanov AV
    Zh Vopr Neirokhir Im N N Burdenko; 2022; 86(3):33-40. PubMed ID: 35758076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical, immunohistochemical, and molecular genetic prognostic factors in adult patients with glioblastoma].
    Lobanova NV; Shishkina LV; Ryzhova MV; Kobyakov GL; Sycheva RV; Burov SA; Lukyanov AV; Omarova ZR
    Arkh Patol; 2016; 78(4):10-19. PubMed ID: 27600777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-institutional external validation of a novel glioblastoma prognostic nomogram incorporating MGMT methylation.
    Molitoris JK; Rao YJ; Patel RA; Kane LT; Badiyan SN; Gittleman H; Barnholtz-Sloan JS; Bentzen SM; Kruser TJ; Huang J; Mehta MP
    J Neurooncol; 2017 Sep; 134(2):331-338. PubMed ID: 28643151
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diffusion Kurtosis Imaging Reflects Glial Fibrillary Acidic Protein (GFAP), Topo IIα, and O⁶-Methylguanine-DNA Methyltransferase (MGMT) Expression in Astrocytomas.
    Wang XC; Lei Y; Wang L; Tan Y; Qin JB; Ma GL; Zhang H
    Med Sci Monit; 2018 Dec; 24():8822-8830. PubMed ID: 30520434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastomas.
    Takeuchi S; Wada K; Toyooka T; Shinomiya N; Shimazaki H; Nakanishi K; Nagatani K; Otani N; Osada H; Uozumi Y; Matsuo H; Nawashiro H
    Neurosurgery; 2013 Jan; 72(1):33-41; discussion 41. PubMed ID: 23096413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IDH1 mutations is prognostic marker for primary glioblastoma multiforme but MGMT hypermethylation is not prognostic for primary glioblastoma multiforme.
    Kalkan R; Atli Eİ; Özdemir M; Çiftçi E; Aydin HE; Artan S; Arslantaş A
    Gene; 2015 Jan; 554(1):81-6. PubMed ID: 25455102
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.